Trial designs and outcome variables in anti-dementia drug testing

  • M. Panisset
  • S. Gauthier
Conference paper
Part of the Key Topics in Brain Research book series (KEYTOPICS)


Designing a protocol for a therapeutic trial in Alzheimer’s disease (AD) is a very complex undertaking and is based on knowledge accumulated over the years about the manifestations of the disease and its diagnostic criteria, its natural history and its pathophysiology. Knowledge about the new compound from its early pre-clinical and clinical phases of development is equally important. Selection of validated outcome variables and a well coordinated project are the other keys for the successful and scientific validation of new medication for the treatment of AD.


Vascular Dementia Clinical Dementia Rate Primary Progressive AphaSia Cerebral Compute Tomography Parkinson Study Group 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. American Psychiatric Association (1987) Diagnostic and statistical manual of mental disorders, 3rd edn revised. American Psychiatric Association, Washington DC, pp 97–164.Google Scholar
  2. Berg L (1988) Clinical dementia rating (CDR). Psychopharmacol Bull 24:637–639.PubMedGoogle Scholar
  3. Boiler F, Becker JT, Holland A, Forbes M, Hood PC, McGonigle-Gibson KL (1991) Predictors of decline in Alzheimer’s disease. Cortex 27:9–17.Google Scholar
  4. Chui HC, Lee Teng E, Henderson VW, Moy AC (1985) Clinical subtypes of dementia of the Alzheimer type. Neurology 35:1544–1550.PubMedGoogle Scholar
  5. Davis KL, Thal LJ, Gamzu ER, et al (1992) A double blind, placebo-controlled multicenter study of Tacrine for Alzheimer’s disease. NEJM 327:1253–1259.PubMedCrossRefGoogle Scholar
  6. Ellenberg JH (1990) Clinical trials. In: Theodore WH (ed) Clinical neuro-pharmacology, neurologic clinics. WB Saunders, Philadelphia, pp 15–30.Google Scholar
  7. Fischer P, Jellinger K, Gatterer G, Danielczyk W (1991) Prospective neuro-pathological validation of Hachinski’s Ischaemic Score in dementias. J Neurol Neurosurg Psychiatry 54:580–583.PubMedCrossRefGoogle Scholar
  8. Folstein MF, Folstein SE, McHugh PR (1975) “Mini Mental State”: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189–198.PubMedCrossRefGoogle Scholar
  9. Forette, F, Panisset M, Boiler F (1992) Clinical trials in cognitive impairment in the elderly. Aging Clin Exp Res 4:239–250.Google Scholar
  10. Francis PT, Palmer AM, Sims NR, Bowen DM, Davison AN, Esiri MM, Neary D, Snowden JS, Wilcock GK (1985) Neurochemical studies of early-onset Alzheimer’s disease. Possible influence on treatment. NEJM 313:7–11.Google Scholar
  11. Galasko D, Abramson I, Corey-Bloom J, Thal LJ (1993) Repeated exposure to the Mini-Mental State Examination and the Information-Memory-Concentration Test results in a proactive effect in Alzheimer’s disease. Neurology 43:1559–1563.PubMedGoogle Scholar
  12. Gauthier S, Bouchard R, Lamontagne A, Bailey P, Bergman H, Ratner J, Tesfaye Y, Saint-Martin M, Bacher Y, Carrier L, Charbonneau R, Clarfield M, Collier M, Dastoor D, Gauthier L, Germain M, Kissel C, Krieger M, Kushnir S, Masson H, Morin J, Nair V, Neirink L, Suissa S (1990) Tetraaminoacridine-lecithin combination treatment in patients with intermediate-stage Alzheimer’s disease. Results of a Canadian double-blind, crossover, multi-center study. NEJM 322:1272–1276.PubMedCrossRefGoogle Scholar
  13. Gauthier S, Gauthier L (1993) What we have learned from the THA trials to facilitate testing of new AChE inhibitors. Prog Brain Res 98:429–527.Google Scholar
  14. Gräsel E, Cameron S, Lehrl S (1990) What contribution can the Hachinski ischrmic scale make to the differential diagnosis between multiinfarct dementia and primary degenerative dementia? Arch Gerontol Geriatr 11:63–75.PubMedCrossRefGoogle Scholar
  15. Growdon JH (1993) Tacrine in Alzheimer’s disease. NEJM 328:810.CrossRefGoogle Scholar
  16. Hamilton M (1967) Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 6:278–295.PubMedCrossRefGoogle Scholar
  17. Hachinski VC, Iliff LD, Zilhka E, Du Boulay GH, McAllister VL, Marshall J, Ross Russell RW, Symon L (1975) Cerebral blood flow in dementia. Arch Neurol 32:632–637.PubMedCrossRefGoogle Scholar
  18. Huang L, Cartwright W, Hu T (1985) The economic cost of senile dementia in the United States. Public Health Rep 1988/103:3–7.Google Scholar
  19. Huff FJ, Becker JT, Belle SH, Nebes RD, Holland AL, Boiler F (1987) Cognitive deficits and clinical diagnosis of Alzheimer’s disease. Neurology 37:1119–1124.PubMedGoogle Scholar
  20. Kukull WA, Larson EB, Reifler BV, Lampe TH, Yerby M, Hughes J (1990) Interrater reliability of Alzheimer’s disease diagnosis. Neurology 40:257–260.PubMedGoogle Scholar
  21. Loeb C, Gandolfo C (1983) Diagnostic evaluation of degenerative and vascular dementia. Stroke 14(3):399–401.PubMedCrossRefGoogle Scholar
  22. Lopez OL, Swihart AA, Becker JT, Reinmuth OM, Reynolds III CF, Rezek DL, Daly III FL (1990) Reliability of NINCDS-ADRDA clinical criteria for the diagnosis of Alzheimer’s disease. Neurology 40:1517–1522.PubMedGoogle Scholar
  23. Lopez OL, Becker JT, Rezek D, Wess J, Boiler F, Reynolds III CF, Panisset M (1992) Neuropsychiatric correlates of cerebral white-matter radiolucencies in probable Alzheimer’s disease. Arch Neurol 49:828–834.PubMedCrossRefGoogle Scholar
  24. Lopez OL, Larumbe MR, Becker JT, Rezek D, Rosen J, Klunk W, DeKosky ST (1994) Reliability of NINDS-AIREN clinical criteria for the diagnosis of vascular dementia. Neurology 44:1240–1245.PubMedGoogle Scholar
  25. Max W (1992) The economic impact of Alzheimer’s disease. Neurology 43 [Suppl 4]:S6–S10.Google Scholar
  26. Mayeux R, Stern Y, Spanton S (1985) Heterogeneity in dementia of Alzheimer type: evidence of subgroups. Neurology 35:453–461.PubMedGoogle Scholar
  27. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of the Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 34:939–944.PubMedGoogle Scholar
  28. Mesulam MM, Weintraub S (1992) Primary Progressive Aphasia: sharpening the focus on a clinical syndrome. In: Boiler F, Forette F, Khachaturian Z, Poncet M, Christen Y (eds), Heterogeneity of Alzheimer’s disease. Springer, Berlin Heidelberg New York Tokyo, pp 43–66.Google Scholar
  29. Morris J (1993) Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 43:2412–2414.PubMedGoogle Scholar
  30. Panisset M (1993) How to detect and confirm dementia. Med N Am 6:490–493.Google Scholar
  31. Panisset M, Roudier M, Saxton J, Boiler F (1994) Severe Impairment Battery: a neuropsychological battery for severely demented patients. Arch Neurol 51:41–45.PubMedCrossRefGoogle Scholar
  32. Parlato V, Panisset M, Lopez OL, Becker JT, Dalla Barba G, Bonavita V, Boiler F (1993) A longitudinal study of memory deficits in probable Alzheimer’s disease and mixed dementia. J Clin Exp Neuropsychol 15:30–31.Google Scholar
  33. Poirier J, Davignon J, Bouthillier D, Kogan S, Bertrand P, Gauthier S (1993) Apolipoprotein E polymorphism and Alzheimer’s disease. Lancet 342:697–699.PubMedCrossRefGoogle Scholar
  34. Reisberg B, Ferris SH, de Leon MJ, Crook T (1982) The Global Deterioration Scale (GDS): an instrument for the assessment of primary degenerative dementia (PDD). Am J Psychiatry 139:1136–1139.PubMedGoogle Scholar
  35. Román GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, Garcia JH, Amaducci L, Orgogozo J-M, Brun A, Hofman A, Moody DM, O’Brien MD, Yamaguchi T, Grafman J, Drayer BP, Bennett DA, Fisher M, Ogata J, Kokmen E, Bermejo F, Wolf PA, Gorelick PB, Bick KL, Pajeau AK, Bell MA, DeCarli C, Culebras A, Korczyn AD, Bogousslavsky J, Hartmann A, Scheinberg P (1993) Vascular dementia: diagnostic criteria for research studies. Neurology 43:250–260.PubMedGoogle Scholar
  36. Rosen WG, Terry RD, Fuld PA, Katzman R, Peck A (1980) Pathological verification of ischemic score in differentiation of dementias. Ann Neurol 7:486–488.PubMedCrossRefGoogle Scholar
  37. Rosen WG, Mohs RC, Davis KL (1984) A new rating scale for Alzheimer’s disease. Am J Psychiatry 141:1356–1364.PubMedGoogle Scholar
  38. Rossor MN, Iversen LL, Reynolds GP, Mountjoy CQ, Roth M (1984) Neurochmical characteristics of early and late onset types of Alzheimer’s disease. Br Med J 288:961–964.CrossRefGoogle Scholar
  39. The Parkinson Study Group (1993) Effects of tocopherol and Deprenyl on the progression of disability in early Parkinson’s disease. NEJM 328:176–183.CrossRefGoogle Scholar

Copyright information

© Springer-Verlag/Wien 1994

Authors and Affiliations

  • M. Panisset
    • 1
  • S. Gauthier
    • 1
  1. 1.McGill Centre for Studies in AgingSt. Mary’s HospitalMontrealCanada

Personalised recommendations